Back to Search Start Over

The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations.

Authors :
Ivanova A
Israel E
LaVange LM
Peters MC
Denlinger LC
Moore WC
Bacharier LB
Marquis MA
Gotman NM
Kosorok MR
Tomlinson C
Mauger DT
Georas SN
Wright RJ
Noel P
Rosner GL
Akuthota P
Billheimer D
Bleecker ER
Cardet JC
Castro M
DiMango EA
Erzurum SC
Fahy JV
Fajt ML
Gaston BM
Holguin F
Jain S
Kenyon NJ
Krishnan JA
Kraft M
Kumar R
Liu MC
Ly NP
Moy JN
Phipatanakul W
Ross K
Smith LJ
Szefler SJ
Teague WG
Wechsler ME
Wenzel SE
White SR
Source :
Journal of biopharmaceutical statistics [J Biopharm Stat] 2020 Nov 01; Vol. 30 (6), pp. 1026-1037. Date of Electronic Publication: 2020 Sep 17.
Publication Year :
2020

Abstract

The Precision Interventions for Severe and/or Exacerbation-prone Asthma (PrecISE) study is an adaptive platform trial designed to investigate novel interventions to severe asthma. The study is conducted under a master protocol and utilizes a crossover design with each participant receiving up to five interventions and at least one placebo. Treatment assignments are based on the patients' biomarker profiles and precision health methods are incorporated into the interim and final analyses. We describe key elements of the PrecISE study including the multistage adaptive enrichment strategy, early stopping of an intervention for futility, power calculations, and the primary analysis strategy.

Details

Language :
English
ISSN :
1520-5711
Volume :
30
Issue :
6
Database :
MEDLINE
Journal :
Journal of biopharmaceutical statistics
Publication Type :
Academic Journal
Accession number :
32941098
Full Text :
https://doi.org/10.1080/10543406.2020.1821705